as 11-15-2024 4:00pm EST
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
To train our stocks GYRE ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
We would greatly appreciate your contribution. Please send an email to [email protected]
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Our GYRE ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"GYRE Forecast & Prediction for November 17, 2024 Gyre Therapeutics Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.